Curon sells patent to gain Nasdaq compliance
This article was originally published in The Gray Sheet
Executive Summary
Patents related to the treatment of Barrett's esophagus were sold to Barrx Medical for $3 mil., $2 mil. of which was cash. The sale should be enough to bring Curon back into compliance with Nasdaq's minimum stockholders' equity requirement, of which Curon had fallen $250,000 short. However, Curon noted that Nasdaq will continue to monitor the firm and it could still be subject to delisting (1"The Gray Sheet" March 20, 2006, p. 21)...